Bausch Health, Canada announced that its topical prescription treatment for acne vulgaris, ARAZLO is now available to patients through BC PharmaCare, the public drug program of British Columbia. ARAZLO is the only tazarotene lotion treatment approved by Health Canada for the topical treatment of acne vulgaris in patients 10 years of age and older. The listing by BC PharmaCare means ARAZLO is now available to patients on all public drug plans across Canada.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
